CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Seagen Inc.
Servier
Daiichi Sankyo
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Shanghai Henlius Biotech
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Seagen Inc.